The efficacy outcomes indicated that the ORR and DCR of the 68 elderly patients with advanced NSCLC who received PD-1 inhibitors were 20.6% and 63.2%, respectively. This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.